Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Goldschmidt, Hartmut [VerfasserIn]   i
 Hegenbart, Ute [VerfasserIn]   i
 Wallmeier, M. [VerfasserIn]   i
 Hohaus, Stefan [VerfasserIn]   i
 Haas, Rainer [VerfasserIn]   i
Titel:Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma
Verf.angabe:H. Goldschmidt, U. Hegenbart, M. Wallmeier, S. Hohaus and R. Haas
E-Jahr:1997
Jahr:September 1997
Umfang:20 S.
Fussnoten:Elektronische Reproduktion der Druck-Ausgabe 29. Oktober 2003 ; Gesehen am 24.04.2025
Titel Quelle:Enthalten in: British journal of haematology
Ort Quelle:Oxford [u.a.] : Wiley-Blackwell, 1955
Jahr Quelle:1997
Band/Heft Quelle:98(1997), 3, Seite 736-755
ISSN Quelle:1365-2141
Abstract:We treated 103 multiple myeloma (MM) patients with 7 g/m2 cyclophosphamide (Cy) followed by 300 μg G-CSF/d to harvest peripheral blood progenitor cells (PBPC). PBPC autografts containing > 2.0 × 106 CD34+ cells per kg body weight were obtained at the first attempt from 90/100 evaluable patients. The most significant factor predicting impairment of PBPC collection was the duration of previous melphalan treatment (P < 0.0001). In multivariate discriminate analysis, treatment with melphalan during the most recent chemotherapy cycles prior to mobilization (P = 0.0727) and previous radiotherapy (P = 0.0628) had a marginally significant negative influence on the efficacy of PBPC collection. We found no reduced functional capacity of CD34+ cells to restore haemopoiesis after myeloablative treatment related to the duration of melphalan exposure. At the time of best response to conventional treatment, a median paraprotein reduction of 21% was achieved following high-dose cyclophosphamide (HD-Cy). Two heavily pretreated patients died and one patient developed pulmonary toxicity W.H.O. grade IV following HD-Cy. Potential transplant candidates should undergo mobilization and harvesting of PBPC before melphalan-containing treatment. Combinations of haemopoietic growth factors and their dose modifications should be investigated to improve PBPC collection, to allow a dosage reduction of the mobilization chemotherapy.
DOI:doi:10.1046/j.1365-2141.1997.2783095.x
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1046/j.1365-2141.1997.2783095.x
 Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1046/j.1365-2141.1997.2783095.x
 DOI: https://doi.org/10.1046/j.1365-2141.1997.2783095.x
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:G-CSF
 high-dose cyclophosphamide
 multiple myeloma
 peripheral blood progenitor cell mobilization
 transplantation
K10plus-PPN:1923583824
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69338791   QR-Code
zum Seitenanfang